Glaukos delivered a beat that was about more than the size of the surprise. The company reported non-GAAP earnings of $0.47 per share against a consensus estimate calling for a $0.12 loss, a 491.7% surprise. Revenue of $211.03 million topped the $168.84 million consensus by 25.0% and grew 58.0% year over year. Earnings grew 393.8% from a year-ago non-GAAP loss of $0.16. Management then raised 2026 sales guidance to $775-$785 million from $680-$700 million and introduced a preliminary 2027 target of $1 billion. The central takeaway is that Glaukos has moved from a launch story to a profitable, cash-generating growth company faster than the Street expected. The open question is now regulatory: whether iDose reimbursement holds.

The quality of the quarter mostly holds up, with caveats. On a GAAP basis, Glaukos earned $0.03 per share, up from a $0.28 loss a year earlier. GAAP operating income was $0.8 million, compared with a $16.4 million operating loss. The gap between GAAP and non-GAAP results came mainly from a $14.1 million resolution agreement with the University of California Regents, $5.9 million of litigation costs, and acquisition amortization. These are real cash and legal costs, but they are not tied to the commercial run rate. Non-GAAP gross margin expanded to 87.7% from 83.9%. Non-GAAP SG&A rose 32% while sales rose 58%, which is genuine operating leverage. Cash, investments, and restricted cash rose $50.5 million sequentially to $339.8 million, with no debt. Management noted that this cash generation surpassed its earlier goal of simply reaching cash-flow breakeven.

Beneath the headline, Epioxa was the swing factor. In its first full quarter after receiving a J-code, the corneal cross-linking therapy generated roughly $53 million, up from about $11 million in Q2. That pushed Corneal Health to $59.0 million, up 154%. Access is broadening quickly:

• Site-of-care coverage reached about 90% of the U.S. population, up from roughly 50% at the end of last year.
• Commercial payer access stands near 90% of lives.
• Medicaid access exceeds 80% of lives, a level management said Photrexa never achieved.
• The net price assumption rose to $65-$70K from a roughly $60K starting point.

U.S. Glaucoma reached $118.6 million, up 47%. iDose contributed about $76 million, despite summer seasonality that modestly tempered its growth, and the full-year iDose outlook edged up to the low $280 millions. Gross margin has climbed for three straight quarters, and management called the level durable, though Q3 included one-time benefits. The weak spot was International Glaucoma, which grew 13.3% year over year but fell 8.9% sequentially. International growth has slowed from 23% in Q1.

The risk ledger is concentrated rather than broad. The proposed iDose local coverage determination (LCD) from Medicare contractors remains unresolved, and they have until roughly May 2027 to finalize or abandon it. Management reiterated that iDose could be flat in 2027 under a restrictive LCD. It also said the $1 billion outlook already absorbs that downside, which is a notable claim given that iDose is one of two growth engines. Spending is also rising. Operating-expense guidance has moved from $555-$565 million to about $630 million, and a significant direct-to-consumer push is planned for 2027, including the Stephen Curry keratoconus awareness campaign. Epioxa prior-authorization friction and strained field support show demand outrunning infrastructure, which is a good problem but still an execution risk. On the catalyst side, the pipeline added positive Phase 4 iDose-plus-cataract data and the RevOpsys retinal license. Phase 2 readouts in Demodex blepharitis and the TKI program are due by year-end, and iDose Trio approval is targeted for late 2027.

The market setup is more complicated than the surprise implies. Investor sentiment improved from -0.17 to -0.11 heading into the report, which still reflects mild skepticism. That skepticism is consistent with LCD worries weighing on positioning. Shares entered the report at $181.17, essentially unchanged from the $180.22 open after the July release. The path between those points was volatile:

• The stock hit a 52-week high of $191.62 in August.
• It slid to $146.39 by early October.
• It then recovered roughly 24% before the report.

The stock sits about 30% above its 200-day moving average and about 5.5% below the August high. In other words, much of the early-October drawdown had already been bought back before these numbers arrived. Earnings Whispers trend readings are largely positive, with sequential growth and momentum improving, while the price trend remains neutral.

The bottom line is that Glaukos produced the kind of quarter that changes the conversation. Earnings swung to a profit, revenue growth was strong enough to force a $90 million guidance raise at the midpoint, and Epioxa now looks like a second legitimate growth engine. Bears retain legitimate ammunition in the pending iDose LCD, rising spending, and a stock that had already rebounded sharply before the print. Still, management's claim that $1 billion in 2027 sales survives a restrictive coverage outcome shifts the debate from whether the company can grow to how much the LCD caps that growth.